New research suggest people can become infected with African Swine Fever Virus and cause illness
http://www.faqs.org/patents/app/20080207875#ixzz1YVVxZ1Ka
"African Swine fever is an endemic disease in sub-Saharan Africa and many other parts of the developing world. It is caused by the African Swine virus that primarily replicates in macrophages and monocytes leading to the impairment of the structure and function of the immune system of the infected organisms. Until now the African Swine epidemic continues to spread despite all efforts to contain it. Thus, there is an objective need for effective, safe and affordable preventive and therapeutic approaches, in particular for effective vaccines, to control and eventually eradicate this disease. Since the characteristic feature of the African Swine virus is to impair the immune system and to cause immune deficiencies in its hosts the development of vaccines and other therapeutic approaches against the African Swine virus has implications for other immune deficiencies or diseases. Several other viruses are also known to cause immunodeficiency-like syndromes in humans, including cytomegalovirus, Epstein Barr Virus and others. Moreover, a series of cases of so-called "idiopathic" immunodeficiencies have been documented that display CD4+T-lymphocytopenia with opportunistic infections, but show no evidence of HIV infection. Since antibodies for the African Swine virus have been detected in humans, the possibility of human infection with the African Swine virus exists and may thus far have escaped any systematic screening. Thus, any preventive and therapeutic approach to African Swine fever can have far-reaching implications to control immune deficiency conditions in humans."
http://www.faqs.org/patents/app/20080207875
Periodic outbreaks of African swine fever virus (ASFV) infection around the world threaten local populations of domestic pigs with lethal disease and provide grounds for pandemic spread. Effective vaccination may bring this threat under control. We investigated the effectiveness of select peptides mimicking viral proteins in establishing a protective immune response. Forty-six synthetic peptides based on the analysis of the complete nucleotide sequence of ASFV were tested for immunogenicity in mice. The 17 best immune response-inducing peptide candidates were selected for further investigation. Twenty-four domestic pigs, 3-4 months old and weighing 20-25 kg, were divided into six groups (n=4) and immunized by subcutaneous injection using a standard three-round injection protocol with one of four peptide combinations prepared from the 17 peptides (Groups 1-4) or with carrier only (Group 5). Group 6, the control, was not vaccinated. Animal body temperature and behavior were monitored during and post immunization for health assessment. Two weeks after the last round of immunizations, the pigs were infected with live ASFV (Espania 70) at 6.0 Ig GAE50/cm3, and the survival rate was monitored. Blood samples were collected for analysis the day before infection and on days 3, 7 and 10 post-infection, or from deceased animals. The serum titers of specific immunoglobulins against synthetic peptides and whole inactivated ASFV were determined by enzyme immunoassay before and after infection. The presence of viral DNA in blood serum samples was determined by polymerase chain reaction. Viral infection activity in blood sera was determined by heme absorption in cultured porcine bone marrow and porcine leukocyte cells. Repeating the injection of synthetic peptides in both the mice and pigs produced an immune response specific to individual peptides, which differed widely in the intensity scale. Specific anti-whole virus immunoglobulin binding activity in the swine serum samples from all groups was below the detection limit. Viral DNA was positively identified in all the samples infected with viral preparations. Viral infection activity was present in all the infected animals and steadily increased with time. On day 3 after infection, the viral titer was significantly lower in Groups 1 and 3 than in the unvaccinated controls. In deceased animals, the viral titer was significantly lower in Groups 1 and 3 than in the controls. All infected animals died within 17 days of infection. The average survival rate was significantly higher in Groups 1 and 3 (12.0 and 14.3 days, respectively) than in the controls (9.8 days). Vaccination with specific synthetic peptides significantly delayed mortality in domestic pigs infected with ASFV. These results justify further investigation aimed at developing an effective vaccine against ASFV infection.
Mol Med Report. 2011 May;4(3):395-401. doi: 10.3892/mmr.2011.454. Epub 2011 Mar 14.
Detection of Novel Sequences Related to African Swine Fever Virus in Human Serum and Sewage.
Loh J, Zhao G, Presti RM, Holtz LR, Finkbeiner SR, Droit L, Villasana Z, Todd C, Pipas JM, Calgua B, Girones R, Wang D, Virgin HW.Departments of Pathology & Immunology and Molecular Microbiology, Department of Medicine and Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Microbiology, Faculty of Biology, University of Barcelona, Barcelona, Spain.
"The family Asfarviridae contains only a single virus species, African swine fever virus (ASFV). ASFV is a viral agent with significant economic impact due to its devastating effects on populations of domesticated pigs during outbreaks, but has not been reported to infect humans. We report here the discovery of novel viral sequences in human serum and sewage which are clearly related to the Asfarvirus family, but highly divergent from ASFV. Detection of these sequences suggests that greater genetic diversity may exist among Asfarviruses than previously thought, and raises the possibility that human infection by Asfarviruses may occur."
J Virol. 2009 Oct 7.Are Pigs the viral source of Kaposi's Sarcoma in Sardinia? Is a ASFV-related Kaposi's Sarcoma epidemic possible in Russia where ASFV is spreading?
(Kaposi's Sarcoma Picture Source: Wikipedia)
The world's highest incidence of Kaposi's sarcoma occurs in Sardinia (Reference) Is it possible that it is due to the fact that African Swine Fever Virus is endemic on the island? (Reference) One study suggests that the incidence of K.S. in northern Sardinia is highest in a countryside area where people have contact with animals. (Reference) Given the high prevalence of HHV-8,--the so-called K.S. herpes virus--in Sardinia (Reference) is it at all possible that HHV-8 may have been misclassified and actually is a human-adapted form of African Swine Fever Virus? (ASFV has been at least visually mistaken for another herpes virus, CMV, in the past.)
A number of experiments could be conducted to explore this hypothesis. In addition to a direct comparison of ASFV and HHV-8, pigs with African Swine Fever Virus could be tested for sequences of HHV-8. People with Kaposi's sarcoma could be tested for sequences of African Swine Fever, including new Asfaviridae sequences recently discovered. (Reference) A comparison of the K.S. lesions in humans and ASFV lesions in pigs might be in order.
Given that African Swine Fever is currently spreading in Russia and is now threatening Europe and China, (Reference) it would be useful to know whether people who are exposed to pigs with ASFV are at increased risk for HHV-8, Kaposi's sarcoma and the other pathologies associated with HHV-8. A study in sub-Saharan Africa where ASFV is endemic and HHV-8 is also endemic (Reference) might be useful. And areas of Russia where ASFV is spreading could be monitored closely for any signs of an increase of K.S. or HHV-8 infection and HHV-8 related pathologies.
HHV-8 is an emerging health problem. HHV-8-associated K.S. is a significant problem in AIDS patients. It may also be the key to Chronic Fatigue Syndrome. HHV-8 has been found in the cerebrospinal fluid of 50% of Chronic Fatigue Syndrome patients. (Reference) HHV-8 has been linked to type 2 diabetes. (Reference) HHV-8 has been detected in B-cells in Castleman's disease and primary effusion lymphoma. (Reference).
If HHV-8 is a form of ASFV, it is possible that pigs might constitute a useful animal model for the study of possible treatments for K.S. and other pathologies associated with HHV-8. And if there is any relationship between ASFV and HHV-8, people may have to be warned to take special precautions around pigs in areas where there are ASFV outbreaks. And countries where undercooked pork is consumed (like Ukraine where salo is a staple) may need to alert the public to cook all pork products thoroughly during ASFV epidemics.
Is this HHV-6 paper that came out of Robert Gallo's lab truth or fraud generated by a conflict of interest?
Below you will learn why Dharam Ablashi and all the scientists Gallo's lab had a major conflict of interest where this virus is concerned. Other labs need to repeat this research. Independent labs all over the world.
John Beldekas
(Photo by Jane Teas)
"In August, 1986, John Beldekas was invited to go to the NCI and present his findings on the link between ASFV [African Swine Fever virus] and AIDS, which he did. Beldekas gave samples of all his lab work to Gallo. Later, the government asked Beldekas to turn over all his reagents and lab work to the government, which he did. Beldekas had found ASFV presence in nine of 21 AIDS patients using two standard procedures. At the meeting, Gallo was reported saying: “we know it is not ASFV.” How could Gallo know this as he hadn’t done any of his own tests to look for ASFV?
Two months later, Gallo published an article in Science (Oct 31, 1986) that he discovered a new possible co-factor in AIDS, a virus he called Human B Cell Lymphotropic Virus which he named HBLV. Like ASFV, HBLV infected B cells and also lived in macrophages. Did Gallo steal Beldekas’s ASF virus he found in AIDS patients and rename it HBLV? Later on, when Gallo found that HBLV could also infect other immune cells, he changed the name of HBLV to HHV-6. Eventually, Gallo identified his HBLV as the variant A strain of HHV-6 and called it a human herpesvirus."
--Mark Konlee
http://www.keephopealive.org/report10.html
https://www.nytimes.com/?WT.z_jog=1&hF=t&vS=undefined
To the Editor: Last September, while conducting a preliminary sociomedical study on acquired immune deficiency syndrome in Rwanda, in the eastern part of central Africa, I was surprised to learn that 50 percent of the pig population had died in an African swine fever epidemic that had begun in December 1983. The epidemic spread northward from Burundi to south-central Rwanda near Butare. This is the same area where Dr. Philippe van de Perre of St. Pierre's Hospital in Brussels and his associates found that 27 of 33 female prostitutes had AIDS or AIDS-related complex, what must certainly be the highest proportion of persons with such symptoms in any at-risk sample yet studied. Eighteen percent of samples of adult blood donors and hospital employees in Kigali, the capital city, were seropositive to human immunodeficiency virus antibody last year. This year, the percentage has increased to 24. Human immunodeficiency virus, in Rwanda at least, appears to be the necessary but not sufficient condition to produce AIDS. Perhaps the African swine fever epidemic and the high rate of illness among prostitutes near Butare is just a coincidence. But, with the recent African swine fever scare caused by the discovery of sickly pigs near Belle Glades, Fla., and with the report by Dr. John Beldekas of Boston University and his associates of some evidence of infection by the African swine fever virus in nearly half of a sample of 21 AIDS patients in the United States, epidemiologists and veterinarians might do well to explore the possibility that this virus is a co-factor in AIDS transmission in central Africa and perhaps other regions of the world. DOUGLAS A. FELDMAN New Haven, July 23, 1986 The writer, a medical anthropologist, is a research fellow at Yale University's Human Relations Area Files Inc.
